|Application ||WB, IF, E|
|Other Accession||NP_004110, 121114304|
|Calculated MW||109 kDa|
|Application Notes||FLT3 antibody can be used for detection of FLT3 by Western blot at 1 - 2 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||FLT3; At least three isoforms of FLT3 are known to exist; this antibody will detect all isoforms.|
|Reconstitution & Storage||FLT3 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||FLT3 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||CD135, FLK2, STK1|
|Function||Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.|
|Cellular Location||Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Note=Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation|
|Tissue Location||Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
FLT3 Antibody: FLT3 is a member of the class III receptor tyrosine kinase family and its internal tandem duplication (ITD) is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. It is a membrane bound glycosylated protein that is expressed primarily in early hematopoietic progenitor cells. Upon binding its ligand FL, FLT3 activates multiple signaling pathways including the PI3K/Akt and Ras/MEK/MAPK pathways. In cells expressing FLT3-ITD, these pathways are constitutively on, resulting in abnormal cell growth and anti-apoptotic activity.
Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993; 82:1110-9
Yokoa S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. Leukemia 1997; 11:1605-9.
Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J. Hematol. and Oncol. 2011; 4:13.
If you have any additional inquiries please email technical services at email@example.com.